These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 17428156)

  • 61. Use of glycoprotein IIb/IIIa platelet inhibitors in peripheral vascular interventions.
    Ansel GM; George BS; Botti CF; Silver MJ
    Rev Cardiovasc Med; 2002; 3 Suppl 1():S35-40. PubMed ID: 12439435
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Safety of tirofiban therapy in very old patients with acute coronary syndrome or non-Q-wave myocardial infarction.
    Graf C; Nkoulou R; Trombert V; Perrenoud JJ
    J Am Geriatr Soc; 2005 Jan; 53(1):172-3. PubMed ID: 15667404
    [No Abstract]   [Full Text] [Related]  

  • 63. Platelet Glycoprotein IIb/IIIa Inhibitor Tirofiban Ameliorates Cardiac Reperfusion Injury.
    Chang ST; Chung CM; Chu CM; Yang TY; Pan KL; Hsu JT; Hsiao JF
    Int Heart J; 2015 May; 56(3):335-40. PubMed ID: 25912900
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Impact of ABO blood groups on tirofiban mediated inhibition of platelet function.
    Feuring M; Harenberg J; Peiter A; Ganschow A; Ruf A; Losel R; Wehling M; Schultz A
    Platelets; 2005 Nov; 16(7):430-4. PubMed ID: 16236604
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Repetitive profound thrombocytopenia after treatment with tirofiban: a case report.
    Eryonucu B; Tuncer M; Erkoc R
    Cardiovasc Drugs Ther; 2004 Nov; 18(6):503-5. PubMed ID: 15770438
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pharmacosimulation of delays and interruptions during administration of tirofiban: a systematic comparison between EU and US dosage regimens.
    Heramvand N; Masyuk M; Muessig JM; Nia AM; Karathanos A; Polzin A; Valgimigli M; Gurbel PA; Tantry US; Kelm M; Jung C
    J Thromb Thrombolysis; 2022 Aug; 54(2):301-308. PubMed ID: 35482154
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Decrease of vascular smooth muscle cell locomotion by abciximab, but not tirofiban: a possible role of different affinity to alpha v beta 3 integrins.
    Blindt R; Bosserhoff AK; Krott N; Vogt F; Hanrath P; Demircan L; vom Dahl J
    Coron Artery Dis; 2002 Nov; 13(7):357-64. PubMed ID: 12488644
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Tirofiban versus abciximab: tirofiban is administered at suboptimal dosages when evaluated in an arterial thrombosis model in non-human primates.
    van Rensburg WJ; Roodt JP; Lamprecht S; Meiring SM; Badenhorst PN
    Clin Exp Med; 2012 Dec; 12(4):257-63. PubMed ID: 22219002
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Safety of Glycoprotein IIb-IIIa Inhibitors Used in Stroke-Related Treatment: A Systematic Review and Meta-Analysis.
    Zhu X; Cao G
    Clin Appl Thromb Hemost; 2020; 26():1076029620942594. PubMed ID: 32727211
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Glycoprotein IIb/IIIa inhibition and long-term benefit: the stuff of dreams?
    Montalescot G
    Eur Heart J; 2004 Sep; 25(18):1562-4. PubMed ID: 15351154
    [No Abstract]   [Full Text] [Related]  

  • 71. Pharmacokinetic modeling of the high-dose bolus regimen of tirofiban in patients with severe renal impairment.
    Lakings DB; Janzen MC; Schneider DJ
    Coron Artery Dis; 2012 May; 23(3):208-14. PubMed ID: 22441136
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Ischemic brain tissue salvaged from infarction by the GP IIb/IIIa platelet antagonist tirofiban.
    Junghans U; Seitz RJ; Ritzl A; Wittsack HJ; Fink GR; Freund HJ; Siebler M
    Neurology; 2002 Feb; 58(3):474-6. PubMed ID: 11839855
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Bleeding risk of tirofiban, a nonpeptide GPIIb/IIIa platelet receptor antagonist in progressive stroke: an open pilot study.
    Junghans U; Seitz RJ; Aulich A; Freund HJ; Siebler M
    Cerebrovasc Dis; 2001; 12(4):308-12. PubMed ID: 11721100
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Platelet Inhibition With IV Glycoprotein IIb/IIIa Inhibitor to Prevent Thrombosis in Pediatric Patients Undergoing Aortopulmonary Shunting.
    Emani S; Pereira LM; Piekarski BL; Diallo F; Chu E; Wesley MC; Thiagarajan R; Emani SM
    Pediatr Crit Care Med; 2020 Jun; 21(6):e354-e361. PubMed ID: 32168298
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment: case report and literature review.
    Elcioglu OC; Ozkok A; Akpınar TS; Tufan F; Sezer M; Umman S; Besısık SK
    Int J Hematol; 2012 Sep; 96(3):370-5. PubMed ID: 22767141
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Acute profound thrombocytopenia associated with tirofiban: clinical approach to diagnosis and therapeutic management].
    Agnelli D; Ottani F
    G Ital Cardiol (Rome); 2008 Feb; 9(2):137-43. PubMed ID: 18383777
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Inhibition of platelet function by abciximab or high-dose tirofiban in patients with STEMI undergoing primary PCI: a randomised trial.
    van Werkum JW; Gerritsen WB; Kelder JC; Hackeng CM; Ernst SM; Deneer VH; Suttorp MJ; Rensing BJ; Plokker HW; Ten Berg JM
    Neth Heart J; 2007; 15(11):375-81. PubMed ID: 18176639
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Massive pulmonary haemorrhage complicating the treatment of acute coronary syndrome.
    Gill DS; Ng K; Ng KS
    Heart; 2004 Mar; 90(3):e15. PubMed ID: 14966076
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Delayed stenting of a thrombotic saphenous vein graft after intravenous tirofiban pretreatment.
    Niccoli G; De Vita M; Maria Leone A; Biscione C; Mongiardo R; Rebuzzi A; Crea F
    Int J Cardiol; 2006 Jun; 110(1):108-9. PubMed ID: 16005993
    [No Abstract]   [Full Text] [Related]  

  • 80. Glycoprotein IIb/IIIa inhibitors and no-reflow.
    Kloner RA; Dai W
    J Am Coll Cardiol; 2004 Jan; 43(2):284-6. PubMed ID: 14736450
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.